Ex Vivo T Cell-Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission

被引：72

作者：

Bayraktar, Ulas D. ^{[1
]}

de Lima, Marcos ^{[1
]}

Saliba, Rima M. ^{[1
]}

Maloy, Molly ^{[2
]}

Castro-Malaspina, Hugo R. ^{[2
]}

Chen, Julianne ^{[1
]}

Rondon, Gabriela ^{[1
]}

Chiattone, Alexander ^{[1
]}

Jakubowski, Ann A. ^{[2
]}

Boulad, Farid ^{[2
,3
]}

Kernan, Nancy A. ^{[2
,3
]}

O'Reilly, Richard J. ^{[2
,3
]}

Champlin, Richard E. ^{[1
]}

Giralt, Sergio ^{[2
]}

Andersson, Borje S. ^{[1
]}

Papadopoulos, Esperanza B. ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[2] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, Adult Bone Marrow Transplantat Serv, New York, NY 10021 USA

[3] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, Pediat Bone Marrow Transplantat Serv, New York, NY 10021 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 06期

关键词：

AML; Stem cell transplantation; T cell depletion; GVHD; Transplant outcomes; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CHRONIC MYELOGENOUS LEUKEMIA; DAILY INTRAVENOUS BUSULFAN; FREE SURVIVAL; HEMATOLOGIC MALIGNANCIES; IMMUNE RECONSTITUTION; DONOR TRANSPLANTATION; POSTREMISSION THERAPY; CLINICAL OUTCOMES;

D O I：

10.1016/j.bbmt.2013.02.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study was conducted to retrospectively compare the clinical outcomes after transplantation of T cell depleted (TCD) and unmodified allografts in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Patients received TCD grafts at Memorial Sloan-Kettering Cancer Center (MSKCC, N = 115) between 2001 and 2010 using the following preparative regimens: hyperfractionated total body irradiation (HFTBI)+thiotepa+fludarabine; HFTBI+thiotepa+cyclophosphamide; or i.v. busulfan+melphalan+fludarabine. TCD was performed by 1 of 2 immunomagnetic CD34(+) cell selection methods for peripheral blood grafts or by soybean lectin agglutination followed by sheep red blood cell-rosette depletion for bone marrow grafts. No additional graft-versus-host disease (GVHD) prophylaxis was administered. Patients received unmodified grafts at M.D. Anderson Cancer Center (MDACC, N = 181) after conditioning with busulfan+fludarabine and GVHD prophylaxis with tacrolimus+mini-methotrexate. Patients with unrelated or human leukocyte antigen mismatched donors received anti-thymocyte globulin (ATG) at both centers, with some recipients of matched related donor TCD transplants also receiving ATG, depending upon the preparative regimen. TCD graft recipients were more likely to be older, receive a mismatched transplant, and have peripheral blood used as the graft source. The incidences rates of grades 2 to 4 acute GVHD and chronic GVHD were significantly lower in the TCD graft group (5% versus 18%, and 13% versus 53%). Three-year relapse-free and overall survival rates were 58% and 57%, respectively, in recipients of TCD grafts, and 60% and 66% in recipients of unmodified grafts (P = not significant). Survival and relapse-free survival are similar after TCD and conventional transplants from related/unrelated donors in patients with AML in CR1, but TCD significantly reduces GVHD. (C) 2013 American Society for Blood and Marrow Transplantation.

引用

页码：898 / 903

页数：6

共 37 条

[1] Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS [J].

Andersson, Borje S. ;

de Lima, Marcos ;

Thall, Peter F. ;

Wang, Xuemei ;

Couriel, Daniel ;

Korbling, Martin ;

Roberson, Soonja ;

Giralt, Sergio ;

Pierre, Betty ;

Russell, James A. ;

Shpall, Elizabeth J. ;

Jones, Roy B. ;

Champlin, Richard E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (06) :672-684

[2] Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse [J].

Aversa, F ;

Terenzi, A ;

Tabilio, A ;

Falzetti, F ;

Carotti, A ;

Ballanti, S ;

Felicini, R ;

Falcinelli, F ;

Velardi, A ;

Ruggeri, L ;

Aloisi, T ;

Saab, JP ;

Santucci, A ;

Perruccio, K ;

Martelli, MP ;

Mecucci, C ;

Reisner, Y ;

Martelli, MF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3447-3454

[3]

Boulad F, 2007, PHASE 2 TRIAL CHEMOT, p2991a

[4]

Champlin RE, 2000, BLOOD, V95, P3996

[5] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? [J].

Cornelissen, Jan J. ;

van Putten, Wim L. J. ;

Verdonck, Leo F. ;

Theobald, Matthias ;

Jacky, Emanuel ;

Daenen, Simon M. G. ;

Kooy, Marinus van Marwijk ;

Wijermans, Pierre ;

Schouten, Harry ;

Huijgens, Peter C. ;

van der Lelie, Hans ;

Fey, Martin ;

Ferrant, Augustin ;

Maertens, Johan ;

Gratwohl, Alois ;

Lowenberg, Bob .

BLOOD, 2007, 109 (09) :3658-3666

[6] Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS [J].

de Lima, M ;

Couriel, D ;

Thall, PF ;

Wang, XM ;

Madden, T ;

Jones, R ;

Shpall, EJ ;

Shahjahan, M ;

Pierre, B ;

Giralt, S ;

Korbling, M ;

Russell, JA ;

Champlin, RE ;

Andersson, BS .

BLOOD, 2004, 104 (03) :857-864

[7] Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303 [J].

Devine, Steven M. ;

Carter, Shelly ;

Soiffer, Robert J. ;

Pasquini, Marcelo C. ;

Hari, Parameswaran N. ;

Stein, Anthony ;

Lazarus, Hillard M. ;

Linker, Charles ;

Stadtmauer, Edward A. ;

Alyea, Edwin P., III ;

Keever-Taylor, Carolyn A. ;

O'Reilly, Richard J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (09) :1343-1351

[8]

DREGER P, 1995, EXP HEMATOL, V23, P147

[9] EFFECT OF T-CELL DEPLETION AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS ON ENGRAFTMENT, RELAPSE, AND DISEASE-FREE SURVIVAL IN UNRELATED MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].

DROBYSKI, WR ;

ASH, RC ;

CASPER, JT ;

MCAULIFFE, T ;

HOROWITZ, MM ;

LAWTON, C ;

KEEVER, C ;

BAXTERLOWE, LA ;

CAMITTA, B ;

GARBRECHT, F ;

PIETRYGA, D ;

HANSEN, R ;

CHITAMBAR, CR ;

ANDERSON, T ;

FLOMENBERG, N .

BLOOD, 1994, 83 (07) :1980-1987

[10] Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients [J].

Fallen, PR ;

McGreavey, L ;

Madrigal, JA ;

Potter, M ;

Ethell, M ;

Prentice, HG ;

Guimaraes, A ;

Travers, PJ .

BONE MARROW TRANSPLANTATION, 2003, 32 (10) :1001-1014

← 1 2 3 4 →